Hexosomes formed from glycerate surfactants - Formulation as a colloidal carrier for irinotecan

被引:118
作者
Boyd, Ben J.
Whittaker, Darryl V.
Khoo, Shui-Mei
Davey, Greg
机构
[1] Monash Univ, Victorian Coll Pharm, Dept Pharmaceut, Parkville, Vic 3052, Australia
[2] Mayne Pharma Ltd, Injectable Prod Dev, Mulgrave, Vic 3170, Australia
关键词
nanostructured lipid carriers; liquid crystalline phases; irinotecan; formulation; in vitro release; DRUG-DELIVERY SYSTEMS; COMPOSITION PHASE-DIAGRAM; METABOLITE SN-38; LACTONE FORMS; CUBIC PHASE; RELEASE; CPT-11; WATER; CUBOSOMES; NANOPARTICLES;
D O I
10.1016/j.ijpharm.2006.03.010
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
A new class of amphiphiles with a glycerate headgroup, recently shown to form reverse hexagonal phase in excess water, have been dispersed to form Hexosome dispersions comprising sub-200 nm particles retaining the internal nanostructure of the parent H-II phase. The application of these novel materials to the development of a new injectable formulation of irinotecan was investigated. The formulation of irinotecan with a small percentage of oleic acid in oleyl glycerate permitted a clinically relevant dose of irinotecan to be dissolved in the glycerate surfactant and dispersed in aqueous medium to form an injectable particle-based dose form of irinotecan. Importantly, incorporation of irinotecan into Hexosomes at neutral pH did not result in conversion from the active lactone to the inactive carboxylate form on storage, and is hence a promising alternative to the current low pH formulation of irinotecan required to inhibit this conversion. Although release of irinotecan from the Hexosomes was shown to be virtually instantaneous from the Hexosomes on substantial dilution, the retention of the drug in lactone form at neutral pH demonstrates a potential application of these novel nanostructured particles in injectable drug delivery. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:154 / 162
页数:9
相关论文
共 30 条
[1]
Glycolipid based cubic nanoparticles: preparation and structural aspects [J].
Abraham, T ;
Hato, M ;
Hirai, M .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2004, 35 (02) :107-117
[2]
B3YD B4, 2004, Patent No. I00J0IIKO0
[3]
Phase behavior of the phytantriol/water system [J].
Barauskas, J ;
Landh, T .
LANGMUIR, 2003, 19 (23) :9562-9565
[4]
Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems [J].
Boyd, BJ ;
Whittaker, DV ;
Khoo, SM ;
Davey, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 309 (1-2) :218-226
[5]
Characterisation of drug release from cubosomes using the pressure ultrafiltration method [J].
Boyd, BJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 260 (02) :239-247
[6]
THE TEMPERATURE-COMPOSITION PHASE-DIAGRAM AND MESOPHASE STRUCTURE CHARACTERIZATION OF MONOPENTADECENOIN IN WATER [J].
BRIGGS, J ;
CAFFREY, M .
BIOPHYSICAL JOURNAL, 1994, 67 (04) :1594-1602
[7]
THE TEMPERATURE-COMPOSITION PHASE-DIAGRAM OF MONOMYRISTOLEIN IN WATER - EQUILIBRIUM AND METASTABILITY ASPECTS [J].
BRIGGS, J ;
CAFFREY, M .
BIOPHYSICAL JOURNAL, 1994, 66 (03) :573-587
[8]
Low viscosity monoglyceride-based drug delivery systems transforming into a highly viscous cubic phase [J].
Chang, CM ;
Bodmeier, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 173 (1-2) :51-60
[9]
Self-assembled "nanocubicle" as a carrier for peroral insulin delivery [J].
Chung, H ;
Kim, J ;
Um, JY ;
Kwon, IC ;
Jeong, SY .
DIABETOLOGIA, 2002, 45 (03) :448-451
[10]
Phase behavior of a monoacylglycerol (Myverol 18-99K)/water system [J].
Clogston, J ;
Rathman, J ;
Tomasko, D ;
Walker, H ;
Caffrey, M .
CHEMISTRY AND PHYSICS OF LIPIDS, 2000, 107 (02) :191-220